Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Fig. 2

Kaplan-Meier curves for overall survival. The median overall survival was 16.4 months (95% confidence interval [CI], 15.3–17.1) for CPB and 12.3 months (95% CI, 10.2–13.5) for CPA (HR 0.69, 95%CI, 0.49–0.99; p = 0.001). *The hazard ratio was calculated using a Cox proportional hazards model, with the age, BMI, haemoglobin < 11 g/dL, histology, IVB CC, duration of drug, performance scores, and number of metastatic sites used as covariates and therapy as the time-dependent factor

Back to article page